Iovance Biotherapeutics
IOVA
IOVA
262 hedge funds and large institutions have $715M invested in Iovance Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 103 increasing their positions, 63 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
7.03% more ownership
Funds ownership: 58.87% → 65.9% (+7%)
4% more funds holding
Funds holding: 252 → 262 (+10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
262
Holding in Top 10
2
Calls
$12M
Puts
$5.94M
Top Buyers
| 1 | +$18.5M | |
| 2 | +$15.9M | |
| 3 | +$9.22M | |
| 4 |
D.E. Shaw & Co
New York
|
+$8.68M |
| 5 |
Morgan Stanley
New York
|
+$8.35M |
Top Sellers
| 1 | -$6.94M | |
| 2 | -$2.97M | |
| 3 | -$2.19M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.12M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2M |
